CritiSense develops technology for the real-time monitoring of patients' metabolic state and as a novel endpoint of resuscitation.
CritiSense was founded in 2004 on the basis of the assets of an earlier company named Vital Medical. The company's device, the Critiview, was developed by the company's co-founder and chief scientist, Professor Avraham Mayevsky, formerly head of the department of Department of Life Sciences and Dean of the Faculty of Natural Sciences at Bar Ilan University, where he established a center for tissue physiology. It provides continuous, real-time multi-parametric physiological data at the tissue and cellular level, by monitoring the mitochondrial function and the microcirculatory blood flow and oxygen saturation, by way of tissue titration therapy with an optical sensor.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 21, 2006 | Series Unknown | $1.20M | 1 | Bridge Investment Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Bridge Investment Fund | Yes | Series Unknown |